The invention relates to apparatus and methods for stimulating living tissues to determine nerve conduction properties using a pair of stimulator probes and a plurality of detection electrodes. The invention overcomes the problem of reporting potentially inaccurate nerve conduction results by detecting a stimulator probe short or shunt condition during nerve conduction tests. Detection of a short or shunt condition between two stimulator probes is accomplished by monitoring the magnitude of the stimulus artifact waveform acquired from the detection electrodes and the voltage difference between the stimulator probes. A test is flagged when magnitude of the stimulus artifact waveform is below a first threshold and voltage difference between the two stimulator probes is below a second threshold. The first and second threshold values are determined based on the known spatial relationship between the stimulator probes and detection electrodes. Feedback is provided to the tester to alert defective test conditions.

Systems and methods provide interface to a patient's autonomic nerves via an interior lumen wall of a blood vessel. Systems can include a probe having at least one electrode for receiving electrical signals from the interior of the lumen wall. The system can include processing components for extracting the signals from noise within the patient's body. Systems can include stimulation electrodes for providing stimulation and eliciting action potentials within the patient and destructive processes for destroying nervous function. The effect of nerve destruction on the propagation of action potentials can be effectively used as a feedback mechanism for determining the amount of nervous function destruction in the patient.

Sensing and/or treating GPs or other components of the ANS. Optionally, sensing is from within the GP, for example, using a helical needle with at least one electrode. Optionally, treatment is by injection of a neuromodulator chemical into the GP. In some embodiments, means are provided to reduce the migration of the neuromodulator away from the GP.

A device positioned in the vagina includes a sensor. The sensor data is used to determine whether a condition is met or exists to trigger a therapeutic response by the device. A device for stimulating nerves adjacent the vagina includes a nerve stimulating element coupled to a main body. The nerve stimulating element is positioned and designed to stimulate the vesical, Frankenhauser's and/or inferior hypogastric plexuses. The device may reside in the vaginal fornices. An implant is also provided which has a nerve stimulating element in contact with a uterosacral ligament. The device positioned in the vagina may be used to charge a power source for an implant, which may be a capacitor.

Neuromuscular monitoring is described that uses a novel lead assembly and a monitor that can select the appropriate electrodes on the lead assembly and calibrate the stimulation signals applied to the patient through the lead assembly. The monitoring can also set a noise floor value to reduce the likelihood of an erroneous train of four ratio.

Neuromuscular monitoring is described that uses a novel lead assembly and a monitor that can select the appropriate electrodes on the lead assembly and calibrate the stimulation signals applied to the patient through the lead assembly. The monitoring can also set a noise floor value to reduce the likelihood of an erroneous train of four ratio.

Methods for treating a condition in a subject, e.g., by enhancing homeostatic capacity of the subject (which may manifest as an increase in a dynamic range of one or more system responses in the subject), are provided. Aspects of embodiments of the methods include: (a) enhancing at least one symptom of the condition to be treated in a manner effective to cause the subject to mount a compensatory response; and (b) diminishing at least one symptom of the condition to be treated; so as to treat the subject for the condition. Also provided are compositions, kits and systems for practicing the subject methods.

The present invention includes systems and methods for measuring, monitoring and treating arrhythmia and cardiac function via the intrinsic cardiac nervous system. The systems and methods compare neural signatures of the intrinsic cardiac nervous system that are associated with both healthy and diseased myocardial tissue to identify and target afferent intrinsic cardiac neurons for which signaling has been affected by diseased cardiac tissue. Accordingly, methods of modulating afferent neural signals from the diseased myocardium to the intrinsic cardiac nervous system, intrathoracic extracardiac ganglia, and higher centers of the cardiac neuraxis are used as a novel therapeutic approach to mitigating ischemic heart disease.

Devices and methods for implanting neural interface technology in mammals are provided. A device can include an array of self-closing channels; two flanges that flank the array of channels, the flanges can be used to open the self-closing channels; and a plurality of cuff electrodes disposed at a circumference of each self-closing channel, the plurality of cuff electrodes being optimally disposed to detect a maximum amplitude of an action potential signal.

Systems, methods and devices for controlled sympathectomy procedures for neuromodulation in the treatment of subjects having neoplastic conditions are disclosed. Systems, methods, and devices for interventionally treating a cancerous tumor and cancer related pain are disclosed.